胰岛素的可及性和可用性:国际糖尿病联合会-中东和北非地区(IDF-MENA)成员协会的一项调查

M. Saad, S. Masood, Nizar Al Bache, S. Odhaib, J. Belkhadir, N. Shegem
{"title":"胰岛素的可及性和可用性:国际糖尿病联合会-中东和北非地区(IDF-MENA)成员协会的一项调查","authors":"M. Saad, S. Masood, Nizar Al Bache, S. Odhaib, J. Belkhadir, N. Shegem","doi":"10.4103/jod.jod_114_22","DOIUrl":null,"url":null,"abstract":"Introduction: One hundred years after its discovery, insulin is still inaccessible for many people living with diabetes. In the recent World Health Organization (WHO) 2021 report on Barriers to Insulin Availability, WHO highlights the alarming state of global access to insulin. According to International Diabetes Federation (IDF), as reported in IDF Atlas, 10th edition, 73 million adult people with diabetes (PWD) live in Middle East and North Africa (MENA) Region. Materials and Methods: A survey was conducted in the International Diabetes Federation (IDF) MENA Region through its Member Associations in 2021. Eighteen countries out of 21 participated. Questions were about insulin support, beneficiaries, local production, insurance coverage, average cost, minimum wage, and barriers to access. Results: Fifty percent of countries had full government support and 44% had partial. In 56 % of countries, support is limited to human insulin, and the majority is restricted to citizens. Some PWDs have difficulties accessing insulin: low-income persons, refugees, noncitizens, or living in remote areas. Approximately 61% of countries have national social security funds and 61% private insurance coverage for insulin. In five countries, there is a law prohibiting nongovernmental organizations to receive international donations of insulin. Local production exists in only five countries surveyed. There is a wide variation in the cost of insulin from $1.42 to 100 and in the minimum wage ($7–2667). Additional barriers to access were delivery, storage, cost, electricity, war conditions, displacements, and sanctions. Conclusion: Although government support is available in the majority of countries, it is still mainly through the provision of human insulin and restricted to citizens. Many barriers affect access to insulin and its costremains unaffordable. Disparities exist between countries within the same classification of income. Mapping the current situation will help to improve it and monitor change. This document can be informative for PWD living or visiting any of these countries and can help understand cross-border travel for medical treatment, and local and regional policies.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"30 1","pages":"73 - 80"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Accessibility and availability of insulin: A survey by International Diabetes Federation-Middle East and North Africa Region (IDF-MENA) Member Associations\",\"authors\":\"M. Saad, S. Masood, Nizar Al Bache, S. Odhaib, J. Belkhadir, N. Shegem\",\"doi\":\"10.4103/jod.jod_114_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: One hundred years after its discovery, insulin is still inaccessible for many people living with diabetes. In the recent World Health Organization (WHO) 2021 report on Barriers to Insulin Availability, WHO highlights the alarming state of global access to insulin. According to International Diabetes Federation (IDF), as reported in IDF Atlas, 10th edition, 73 million adult people with diabetes (PWD) live in Middle East and North Africa (MENA) Region. Materials and Methods: A survey was conducted in the International Diabetes Federation (IDF) MENA Region through its Member Associations in 2021. Eighteen countries out of 21 participated. Questions were about insulin support, beneficiaries, local production, insurance coverage, average cost, minimum wage, and barriers to access. Results: Fifty percent of countries had full government support and 44% had partial. In 56 % of countries, support is limited to human insulin, and the majority is restricted to citizens. Some PWDs have difficulties accessing insulin: low-income persons, refugees, noncitizens, or living in remote areas. Approximately 61% of countries have national social security funds and 61% private insurance coverage for insulin. In five countries, there is a law prohibiting nongovernmental organizations to receive international donations of insulin. Local production exists in only five countries surveyed. There is a wide variation in the cost of insulin from $1.42 to 100 and in the minimum wage ($7–2667). Additional barriers to access were delivery, storage, cost, electricity, war conditions, displacements, and sanctions. Conclusion: Although government support is available in the majority of countries, it is still mainly through the provision of human insulin and restricted to citizens. Many barriers affect access to insulin and its costremains unaffordable. Disparities exist between countries within the same classification of income. Mapping the current situation will help to improve it and monitor change. This document can be informative for PWD living or visiting any of these countries and can help understand cross-border travel for medical treatment, and local and regional policies.\",\"PeriodicalId\":15627,\"journal\":{\"name\":\"Journal of Diabetology\",\"volume\":\"30 1\",\"pages\":\"73 - 80\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jod.jod_114_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jod.jod_114_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在胰岛素被发现100年后,许多糖尿病患者仍然无法获得胰岛素。在世界卫生组织(世卫组织)最近发布的《2021年关于胰岛素可获得性障碍的报告》中,世卫组织强调了全球胰岛素可获得性的惊人状况。根据国际糖尿病联合会(IDF)在IDF图集第10版的报告,7300万成年糖尿病患者(PWD)生活在中东和北非(MENA)地区。材料和方法:2021年在国际糖尿病联合会(IDF)中东和北非地区通过其成员协会进行了一项调查。21个国家中有18个参加。问题涉及胰岛素支持、受益人、当地生产、保险范围、平均成本、最低工资和获取障碍。结果:50%的国家得到了政府的全力支持,44%的国家得到了部分支持。在56%的国家,支持仅限于人用胰岛素,大多数仅限于公民。一些残疾人难以获得胰岛素:低收入者、难民、非公民或生活在偏远地区。大约61%的国家拥有国家社会保障基金,61%的国家拥有胰岛素私人保险。在五个国家,有法律禁止非政府组织接受国际捐赠的胰岛素。在接受调查的国家中,只有五个存在本地生产。胰岛素的价格从1.42美元到100美元不等,最低工资(7-2667美元)也有很大差异。其他障碍包括运输、储存、成本、电力、战争条件、流离失所和制裁。结论:虽然大多数国家都有政府支持,但仍然主要是通过提供人胰岛素,并且仅限于公民。许多障碍影响胰岛素的获取,其成本仍然难以承受。在同一收入分类的国家之间存在着差距。绘制当前的情况将有助于改进它并监测变化。本文件可为在上述任何国家生活或访问的残疾人士提供资料,并可帮助他们了解跨境医疗旅行,以及当地和区域政策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Accessibility and availability of insulin: A survey by International Diabetes Federation-Middle East and North Africa Region (IDF-MENA) Member Associations
Introduction: One hundred years after its discovery, insulin is still inaccessible for many people living with diabetes. In the recent World Health Organization (WHO) 2021 report on Barriers to Insulin Availability, WHO highlights the alarming state of global access to insulin. According to International Diabetes Federation (IDF), as reported in IDF Atlas, 10th edition, 73 million adult people with diabetes (PWD) live in Middle East and North Africa (MENA) Region. Materials and Methods: A survey was conducted in the International Diabetes Federation (IDF) MENA Region through its Member Associations in 2021. Eighteen countries out of 21 participated. Questions were about insulin support, beneficiaries, local production, insurance coverage, average cost, minimum wage, and barriers to access. Results: Fifty percent of countries had full government support and 44% had partial. In 56 % of countries, support is limited to human insulin, and the majority is restricted to citizens. Some PWDs have difficulties accessing insulin: low-income persons, refugees, noncitizens, or living in remote areas. Approximately 61% of countries have national social security funds and 61% private insurance coverage for insulin. In five countries, there is a law prohibiting nongovernmental organizations to receive international donations of insulin. Local production exists in only five countries surveyed. There is a wide variation in the cost of insulin from $1.42 to 100 and in the minimum wage ($7–2667). Additional barriers to access were delivery, storage, cost, electricity, war conditions, displacements, and sanctions. Conclusion: Although government support is available in the majority of countries, it is still mainly through the provision of human insulin and restricted to citizens. Many barriers affect access to insulin and its costremains unaffordable. Disparities exist between countries within the same classification of income. Mapping the current situation will help to improve it and monitor change. This document can be informative for PWD living or visiting any of these countries and can help understand cross-border travel for medical treatment, and local and regional policies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信